Pfizer, BioNTech’s coronavirus immunizations get FDA’s ‘most optimized plan of attack’ status Kumar Jeetendra | July 13, 2020 The candidates, both BNT162b1 and BNT162b2, would be the most complex of at least four vaccines getting analyzed by most firms in ongoing trials in the United States and Germany. Pfizer’s shares were up roughly 2% and U.S.-listed stocks of BioNTech were up roughly 6 percent before the bell. Earlier this month, the firms said …
Biocon’s accomplice Equillium plans Itolizumab’s worldwide clinical preliminary for COVID-19 Kumar Jeetendra | July 13, 2020 Biocon’s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND). Itolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory …
Novartis fixes viewpoint as second-quarter deals, benefit fall Kumar Jeetendra | July 21, 2020 Swiss drugmaker Novartis reduced its 2020 sales outlook on Tuesday after second quarter earnings and profit fell, as hospitals which stocked up on medicines during the first-quarter on account of this COVID-19 pandemic slowed buys. Net income in the three months through June dropped 4% to $1.9 billion, compared to $2.1 billion in 2019. Earnings …
US signs contract with Pfizer for COVID-19 antibody dosages Kumar Jeetendra | July 22, 2020 Wellbeing and Human Services Secretary Alex Azar declared on Wednesday that the US has marked an agreement with Pfizer for conveyance in December of the initial 100 million dosages of a COVID-19 antibody the pharmaceutical organization is attempting to create. The US could purchase another 500 million portions under the understanding, Azar said. “Presently those …
Roche’s Tocilizumab neglects to meet essential end focuses for COVID-19 related pneumonia Kumar Jeetendra | July 29, 2020 Swiss Drug maker Roche on July 29 declared that its drug Actemra (Tocilizumab), which has emerged as a widely prescribed drug for treating hosiptalised COVID-19 patients, didn’t fulfill its primary endpoint of improved clinical standing in hospitalised adult patients with acute COVID-19 related pneumonia. In addition, the primary secondary endpoint of decreased patient mortality week …
First coronavirus positive pet canine in US bites the dust: Report Kumar Jeetendra | July 31, 2020 A German shepherd,’Buddy’, that was the first confirmed instance of this novel coronavirus infection in a pet in america has expired, according to a report. In June, the United States Department of Agriculture’s (USDA) National Veterinary Services Laboratories (NVSL) had declared that the pet being the first pet in America testing positive for the virus …
U in Discussions to Procure Sanofi Bargain for coronavirus vaccine Kumar Jeetendra | August 1, 2020 Sanofi SA and GlaxoSmithKline Plc on Friday said they are in advanced discussions to supply up to 300 million doses of an experimental COVID-19 vaccine to the 27-country European Union. Equipped with an emergency fund of more than 2 billion euros (Â#1.80 billion), the European Commission would like to strike deals up to six drugmakers …
Working together with govt organizations to create treatment for COVID-19: Cipla Kumar Jeetendra | August 5, 2020 Medication major Cipla is working together with government agencies to come up with a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company’s chairman YK Hamied. Sharing information with business’s shareholders at the drug firm’s annual report for 2019-20, Hamied said the company is at the forefront …
Swiss Parenterals Limited received European Union (EU) GMP approval Kumar Jeetendra | August 8, 2020 India’s leading manufacturer of Sterile Injectables company to soon enter the EU markets with various range of injectables and expand gradually. Swiss Parenterals Limited, one of the India’s leading sterile injectable manufacturer has received the European Union (EU) GMP for its two state of the art manufacturing facilities located at Bavla in Gujarat. The certification …
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Kumar Jeetendra | August 20, 2020 India, Mumbai, August 20th , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due …
Zydus Cadila gets USFDA gesture for numerous sclerosis treatment drug Kumar Jeetendra | September 26, 2020 Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing. Zydus Cadila said in its approval, the USFDA noted that Zydus …
Lupin gets USFDA gesture to showcase drug for treating backsliding various sclerosis Kumar Jeetendra | October 6, 2020 The company has received approval from the United States Food and Drug Administration (USFDA) to advertise its own Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement. The item is a generic version of Biogen Inc”s Tecfidera delayed-release capsules at the same strengths, it added. The …
